Medtronic reports that demand for valve procedures, particularly TAVR, has stabilized in the U.S. after a brief slowdown linked to low-risk data and market dynamics, guiding a steadier near-term outlook. The company is accelerating investment in DASI software within Structural Heart, supported by leadership changes and momentum, with a focus on mitral and tricuspid capabilities and an optimistic path forward.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What did management say about Valve procedures demand and DASI software?
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Medtronic's FY27 organic growth target of 5.5%-6% (excluding the extra selling week) rests on sustained CAS momentum and a diversified driver set across Neuroscience, Cardiovascular, and MiniMed/MedSurg contributions, supported by CRM innovations and Ardian growth.
Sources used
Research questionWhat drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Answer outline
Medtronic's Q4 2026 commentary indicates valve procedures demand has stabilized after a slowdown, with U.S. headwinds from low-risk data and large-size valve use. Management also underscores a strategic, accelerating investment in DASI software for mitral and tricuspid care, signaling execution momentum and an optimistic outlook.
Sources used
Research questionWhat did management say about Valve procedures demand and DASI software?
Answer outline
Medtronic pins FY27 organic growth at about 5.5% to 6%, supported by Neuroscience acceleration and sustained MedSurg momentum, while CAS remains a strong contributor. MiniMed adds a modest uplift, and the company emphasizes that CAS will not slow, underpinning the diversified path to the target.
Sources used
Research questionWhat drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Answer outline
Medtronic asserts that Affera utilization is strongest at high-volume centers, with 75% of the U.S. installed base and ongoing expansion through additional systems and broader penetration into lower-volume sites. Management ties utilization to quarterly pull-through and notes the installed-base ramp is in early innings, supported by clinical evidence, reimbursement, and ecosystem initiatives to unlock a larger market opportunity.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
Medtronic reports robust Q1 2027 base business outside CAS, led by CRM, CST, and Surgical, with Altaviva offsetting SNM softness. The Cornerstone investment is a $700 million global initiative driving long-term growth, but near-term revenue timing is not disclosed, and management reduced the operating-margin expansion guidance by about 10 bps to fund reinvestments.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic reports a broad-based uplift in its base business excluding CAS for Q1 FY2027, led by CRM, CST, and Surgical strengths, with Altaviva beginning to contribute as reimbursement and training efforts scale. The Cornerstone investment is framed as a longer-term, globally focused platform that may deliver revenue gradually, while the company trims near-term operating-margin expansion by ~10 basis points to fund growth initiatives. Organic revenue guidance is raised despite the investment backdrop.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic indicates Affera utilization expansion is in the early adopters stage, driven by high-volume centers with room to penetrate lower-volume accounts. Management notes strong pull-through within existing large accounts, rapid installed-base growth, and the perception of Affera as a workhorse technology, while acknowledging the lack of precise utilization metrics to quantify pace or ceiling.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
BDX management outlines growth through product-driven platforms, spotlighting sustained APM momentum and expanding contributions from tissue regeneration, pharmacy automation, and biologics. They describe double-digit APM growth driven by HemoSphere Alta adoption and increased commercial investment, while reallocating R&D and resources toward growth vectors, with Analyst Day expected to reveal the integration of APM monitoring with the Alaris pump ecosystem.
Sources used
Research questionWhat did management say about Product drivers and APM momentum?
Answer outline
BioMarin is set to release pivotal Phase 3 results for hypochondroplasia and ENPP1 deficiency in Q2 2026, marking significant milestones in their development pipeline.
Sources used
Research questionWhat are the upcoming pipeline milestones for hypochondroplasia and ENPP1 that BioMarin plans to present in Q2 2026?
Answer outline
Bristol-Myers Squibb anticipates key clinical milestones in 2026 that could influence its growth guidance, with late-year pivotal readouts in thrombosis, Alzheimer's, and multiple myeloma shaping future projections.
Sources used
Research questionWhat are the key clinical milestones Bristol-Myers Squibb aims to achieve in 2026 that could influence its guidance?
Answer outline
Moderna did not set a numeric approval threshold or confirm a 2027 pivotal-data timeline for mRNA-4359 in melanoma. For mRNA-2808, management highlighted safety, response occurrence and durability in heavily pretreated myeloma, but did not provide numeric success criteria or describe a plan to study the therapy earlier in the treatment pathway.
Sources used
Research questionFor mRNA-4359, what efficacy bar would support approval in first- or second-line melanoma, and could it produce pivotal data in 2027? For the T-cell engager in multiple myeloma, what would constitute positive data in a refractory population, and is there a strategy to study it earlier in the treatment pathway?
Answer outline
Management frames ASP risk as manageable and not a threat to physician reimbursement, citing the aim to preserve patient access and cost effectiveness. The GLOBE demonstration is viewed as an alternative payment mechanism that should not erode ASP or physician compensation, and Cencora plans selective, oncology- and retina-focused MSO investments while awaiting policy details.
Sources used
Research questionWhat did management say about Policy ASP risk and GLOBE?
Answer outline
Dafinchi